PHILIPS NV |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.51 EUR | +0.26% |
|
-1.14% | +15.31% |
| Jul. 01 | New semester, new state of mind |  |
| Jun. 28 | PHILIPS NV : JP Morgan reiterates its Neutral rating | ZD |
| Sales 2024 * | 18.71B 20.1B | Sales 2025 * | 19.68B 21.15B | Capitalization | 21.87B 23.51B |
|---|---|---|---|---|---|
| Net income 2024 * | 193M 207M | Net income 2025 * | 1.17B 1.26B | EV / Sales 2024 * | 1.44 x |
| Net Debt 2024 * | 5.07B 5.45B | Net Debt 2025 * | 4.9B 5.27B | EV / Sales 2025 * | 1.36 x |
| P/E ratio 2024 * |
133
x | P/E ratio 2025 * |
21.1
x | Employees | 69,656 |
| Yield 2024 * |
3.47% | Yield 2025 * |
3.68% | Free-Float | 83.42% |
More Fundamentals
* Assessed data
More news
Latest transcript on Philips NV
More press releases
More news
| 1 day | +0.26% | ||
| 1 week | -4.24% | ||
| Current month | -0.34% | ||
| 1 month | -5.51% | ||
| 3 months | +30.67% | ||
| 6 months | +15.31% | ||
| Current year | +15.31% |
1 week
23.05
24.56
1 month
23.0525.05
Current year
17.4928.14
1 year
15.9428.14
3 years
11.2338.88
5 years
11.2347.19
10 years
11.2347.19
| Managers | Title | Age | Since |
|---|---|---|---|
Roy Jakobs
CEO | Chief Executive Officer | 50 | 09-12-31 |
| Director of Finance/CFO | 62 | 86-12-31 | |
Shez Partovi
CTO | Chief Tech/Sci/R&D Officer | 57 | 21-03-21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 14-12-31 |
Sanjay Poonen
BRD | Director/Board Member | 55 | 21-12-31 |
| Director/Board Member | 68 | 21-04-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.00% | 342 M€ | +17.75% | ||
| 1.41% | 15 M€ | -5.61% | ||
| 0.99% | 21 M€ | +9.30% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-02 | 23.51 | +0.26% | 1,344,812 |
| 24-07-01 | 23.45 | -0.59% | 1,187,667 |
| 24-06-28 | 23.59 | -1.30% | 1,717,055 |
| 24-06-27 | 23.9 | -0.67% | 1,826,771 |
| 24-06-26 | 24.06 | +1.18% | 1,721,650 |
Real-time Euronext Amsterdam, July 02, 2024 at 11:35 am EDT
More quotes
Koninklijke Philips N.V. is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. The group leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Koninklijke Philips N.V. is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care.
Calendar
2024-07-29
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
HOLD
Number of Analysts
17
Last Close Price
23.45
EUR
Average target price
25.45
EUR
Spread / Average Target
+8.52%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +15.31% | 23.45B | |
| +0.59% | 207B | |
| +3.92% | 181B | |
| +30.07% | 155B | |
| +32.42% | 112B | |
| +1.98% | 64.42B | |
| +19.65% | 54.38B | |
| -1.86% | 47.43B | |
| -9.53% | 37.17B | |
| -1.28% | 34.81B |
- Stock Market
- Equities
- PHIA Stock
